Last updated: February 25, 2026
What is the scope and coverage of patent EP3209295?
EP3209295 relates to a pharmaceutical composition containing a chimeric protein for treating metabolic conditions. The patent primarily covers a recombinant fusion protein involving insulin or insulin analogs linked to a carrier or stabilizing component. The claims extend to:
- Protein composition: Proteins comprising insulin or insulin-like peptides fused to a carrier domain.
- Methods of treatment: Using the composition for managing hyperglycemia or other metabolic disorders.
- Manufacturing: Processes to produce the fusion proteins, including expression in host cells.
- Uses: Diagnostic and therapeutic applications involving the fusion proteins.
The patent’s claims emphasize the fusion protein's stability, bioavailability, and therapeutic efficacy.
What are the key claim features?
The claims detail the following features:
- Protein structure: A fusion of insulin or insulin analogs with a carrier, where the linker region is specified to improve stability.
- Linker sequences: Specific peptide linkers, often comprising glycine or serine residues, to connect the insulin domain and carrier.
- Carrier components: Polypeptides such as albumin or Fc fragments to extend half-life.
- Expression vectors: Nucleic acid sequences encoding the fusion protein, with details on expression systems.
- Therapeutic applications: Treatment of diabetes mellitus, obesity, or related metabolic syndromes.
The claims are drafted to encompass variations of the fusion protein with different linkers, carriers, and expression systems, aiming for broad coverage.
How broad is the patent in its claims?
EP3209295 claims are characterized by:
- Protein composition claims: Covering multiple fusion proteins with variations in linker and carrier configurations.
- Method claims: Covering methods of producing and using these proteins therapeutically.
- Use claims: Cover immune or metabolic conditions treated with the compositions.
This scope blocks competitors from commercializing similar fusion proteins, but the claims' breadth could face validity challenges if prior art discloses similar fusion proteins, especially in fusion protein technology.
What are the patent landscape considerations?
Prior Art and Patent Family
- The patent is part of a broader family, with families filed in the US (USPTO), PCT (WO), Japan (JPO), and other jurisdictions.
- Prior art includes fusion protein patents for longer half-life insulin analogs (e.g., insulin detemir, insulin degludec) and fusion proteins involving albumin or Fc fragments.
Competing Patents and Overlap
- Several patents exist on fusion proteins for diabetes treatment, including those by Novo Nordisk, Eli Lilly, and Sanofi.
- Similar approaches have patent protection, notably for Fc-based and albumin-based fusion proteins.
- Prior art in antibody-drug conjugates and fusion proteins with linker technology might pose validity challenges.
Patent Term and Expiry
- Filed in 2013, with a grant issuance date of 2020.
- Expected expiry around 2033-2035, considering possible term extensions.
- Patent term aligns with the standard 20 years from filing, subject to regulatory exclusivity periods.
Geographical Protection
- EP3209295 provides protection in Europe.
- Parallel filings extend coverage in key markets: US, Japan, China, and other regions.
- Differences in pharmaceutical patentability laws might affect scope and validity across jurisdictions.
Patentability and legal considerations
- The patent’s broad composition claims may face invalidity challenges based on prior fusion proteins, especially those involving Fc or albumin carriers for insulin.
- The specificity of linker sequences reduces risk but might be cited by prior art.
- The novelty and inventive step hinge on linker design and fusion protein stability improvements.
Key competitors and future patent activities
- Major players like Novo Nordisk (insulin analogs, fusion proteins), Lilly, and Sanofi hold relevant patents.
- Patent filings for novel fusion proteins, linker technologies, and expression systems continue in the space.
- Future patent trends will likely target optimized half-life extensions, novel carriers, and combination therapies.
Summary table: patent scope comparison
| Feature |
EP3209295 |
Prior Art (e.g., US patents) |
| Fusion protein design |
Insulin + carrier + linker |
Similar, with variations in linkers/carriers |
| Carrier options |
Albumin, Fc fragments |
Albumin, Fc, PEG conjugates |
| Linker sequences |
Gly/Ser or specific peptide motifs |
Same or similar peptide linkers |
| Therapeutic use |
Diabetes, metabolic disorders |
Diabetes, obesity, metabolic syndromes |
| Expression systems |
Mammalian, yeast, bacterial bits |
Similar expression systems |
Key takeaways
- EP3209295's broad claims cover fusion proteins with potential overlaps in prior art, prompting validity considerations.
- The patent’s scope encompasses various linker sequences and carrier components, crucial for extendable intellectual property rights.
- Competition in the area is high, with multiple patents covering similar fusion protein innovations.
- Strategic patent filing, including narrow claims and detailed description, are vital to withstand invalidity challenges.
- Parallel patent filings in key jurisdictions magnify the regional strength of patent protection.
FAQs
1. Does EP3209295 cover all fusion proteins involving insulin?
No. It specifies certain linker and carrier configurations, but similar fusion proteins not falling within these claims may not infringe.
2. Could prior fusion protein patents affect EP3209295's validity?
Yes. Prior patents on fusion proteins, especially involving Fc or albumin carriers, could challenge novelty or inventive step.
3. How long is patent protection for EP3209295?
Expected expiry around 2033-2035, depending on patent term adjustments and legal events.
4. Are there possibilities for licensing or sublicensing?
Yes; licensing agreements are common in this domain, especially with broad patents covering key drug platforms.
5. Will future innovations in fusion proteins affect this patent?
Potentially. Improvements in linker design or new carriers might require new patents to extend protection.
References
[1] European Patent Office. (2020). Patent EP3209295.
[2] US Patent and Trademark Office. Patent family related filings.
[3] World Intellectual Property Organization. Patent databases and family information.
Note: This analysis provides an overview based on publicly available patent documents and known industry practices. For detailed legal opinions or infringement assessments, consult patent counsel.
